Most Read Articles
Roshini Claire Anthony, 20 May 2020

The combination of olaparib and bevacizumab as maintenance therapy for advanced ovarian cancer appears to confer the greatest progression-free survival (PFS) benefit in women without residual macroscopic disease following upfront cytoreductive surgery, according to an analysis of the phase III PAOLA-1* trial.

High gestational blood glucose ups risk of preterm birth, macrosomia

23 Apr 2020

A higher level of gestational glycated haemoglobin A1c (HbA1c) within the normal range is associated with preterm birth, macrosomia and large for gestational age (LGA), suggests a recent study, adding that interventions aimed at reducing HbA1c may help prevent adverse birth outcomes.

The investigators abstracted data from the Information System of Guangdong Women and Children Hospital in China from September 2014 to March 2018 to examine the relationship between HbA1c within the normal range and the risk of adverse birth outcomes, namely preterm birth, macrosomia and LGA. In total, 5,658 pregnant women with normal gestational HbA1c met the inclusion criteria.

Of the participants, 261 (4.6 percent) had preterm birth, 200 (3.5 percent) had macrosomia, and 325 (5.7 percent) had LGA. On multivariable logistic regression model, each 1-percent increase in maternal HbA1c positively correlated with a higher risk of preterm birth (odds ratio [OR], 1.58, 95 percent confidence interval [CI], 1.08–2.31), macrosomia (OR, 1.70, 95 percent CI, 1.10–2.64) and LGA (OR, 1.38, 95 percent CI, 0.98–1.96).

Of note, the association between gestational HbA1c and preterm birth was seen more often among women with prepregnancy body mass index ≤24 kg/m2.

“Higher blood glucose level during gestational periods has been consistently associated with increased risk of adverse birth outcomes,” the investigators said. “Evidence regarding the association between higher HbA1c within the normal range and adverse birth outcomes is limited.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 20 May 2020

The combination of olaparib and bevacizumab as maintenance therapy for advanced ovarian cancer appears to confer the greatest progression-free survival (PFS) benefit in women without residual macroscopic disease following upfront cytoreductive surgery, according to an analysis of the phase III PAOLA-1* trial.